Genmab — Februar 2019
-
Fra SGENs earnings: innovaTV 204 Pivotal Trial Enrollment: Seattle Genetics and Genmab expect to complete enrollment by mid-2019 in the pivotal innovaTV 204 trial evaluating TV in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.
-
-
https://www.clinicaltrials.gov/ct2/show/NCT03786081?term=Humax+tf&rank=4 Kombi med Keytruda, Avastin og Carboplatin. I mine øjne er de to sidstnævte voldsomme midler sammen med TF - men valgt fordi de sikkert anvendes i dag i indikationen. Havde hellere set dara
-
Måske vi skal kigge mod Merck https://www.fiercepharma.com/pharma/merck-s-big-m-a-dry-spell-isn-t-for-lack-trying-ceo
-
God morgen. :-). DB skifter focus fra amerikanske aktier til EU aktier. Bla. sundhed. https://danskebank.dk/privat/news/investeringsnyt/forside---investeringsnyt/nu-slaar-vi-til-paa-europaeisk-aktietilbud?sc_cid=em|apsis|pb-art-invest-na-62019|1
-
https://www.linkedin.com/feed/update/urn:li:activity:6499650791236784128 Tisotumab med kommentarer mv
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind